Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial

已完结 10 由 xinxin 发布于 2024/6/15 8:32:34

DOI:10.1038/s41467-024-49092-5
作者：Mary M. McDermott, Christopher R. Martens, Kathryn J. Domanchuk, Dongxue Zhang, Clara B. Peek, Michael H. Criqui, Luigi Ferrucci, Philip Greenland, Jack M. Guralnik, Karen J. Ho, Melina R. Kibbe, Kate Kosmac, Donald Lloyd-Jones, Charlotte A. Peterson, Robert Sufit, Lu Tian, Stephanie Wohlgemuth, Lihui Zhao, Pei Zhu, Christiaan Leeuwenburgh
文献类型：期刊论文
补充材料：只需要正文

Nature

Abstract：People with lower extremity peripheral artery disease (PAD) have increased oxidative stress, impaired mitochondrial activity, and poor walking performance. NAD+ reduces oxidative stress and

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:SpringerExercise Therapy for Peripheral Artery Disease.